Abdominal aortic aneurysm growth rates are not correlated to body surface area in screened men.

BACKGROUND: Screening for abdominal aortic aneurysm (AAA) in 65-year-old males reduces aneurysm related mortality. Infrarenal aortic diameter (IAD) has been shown to correlate to body surface area (BSA) which could influence diagnostic criteria for AAA. This study investigates whether AAA growth rates are also dependent on BSA, as that might have potential effects on surveillance of small AAAs. METHODS: We conducted a retrospective, single center cohort study of 301 men with screening detected AAA between 2010-2017 with surveillance to 2021. AAA growth rates were analyzed in relation to the subject's BSA, smoking habits, and diabetic disease using a linear mixed-effects model. All men were offered smoking cessation program, optimized medical treatment, and advice on physical activity. RESULTS: The screening program included 28,784 men. Of the 22,819 (79%) attending the examinations, 374 men (1.6%) were found to have an AAA out of which 301 men had undergone two or more examinations during surveillance and were included with a median follow-up of 1846 days (IQR: 1 399). Mean unadjusted AAA growth rate was 1.60 mm/year (95% CI: 1.41-1.80). Diabetes mellitus had a statistically significant negative impact, smoking had a statistically significant positive impact on AAA growth rates whereas no correlation between AAA growth rate and BSA could be found. CONCLUSIONS: Body surface area could not be found to have a statistically significant correlation to AAA growth rates. The impact of smoking and diabetes on AAA growth rates remains similar to previously reported.

Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease.

BACKGROUND: The results of a recent meta-analysis aroused concern about an increased risk of death associated with the use of paclitaxel-coated angioplasty balloons and stents in lower-limb endovascular interventions for symptomatic peripheral artery disease. METHODS: We conducted an unplanned interim analysis of data from a multicenter, randomized, open-label, registry-based clinical trial. At the time of the analysis, 2289 patients had been randomly assigned to treatment with drug-coated devices (the drug-coated-device group, 1149 patients) or treatment with uncoated devices (the uncoated-device group, 1140 patients). Randomization was stratified according to disease severity on the basis of whether patients had chronic limb-threatening ischemia (1480 patients) or intermittent claudication (809 patients). The single end point for this interim analysis was all-cause mortality. RESULTS: No patients were lost to follow-up. Paclitaxel was used as the coating agent for all the drug-coated devices. During a mean follow-up of 2.49 years, 574 patients died, including 293 patients (25.5%) in the drug-coated-device group and 281 patients (24.6%) in the uncoated-device group (hazard ratio, 1.06; 95% confidence interval, 0.92 to 1.22). At 1 year, all-cause mortality was 10.2% (117 patients) in the drug-coated-device group and 9.9% (113 patients) in the uncoated-device group. During the entire follow-up period, there was no significant difference in the incidence of death between the treatment groups among patients with chronic limb-threatening ischemia (33.4% [249 patients] in the drug-coated-device group and 33.1% [243 patients] in the uncoated-device group) or among those with intermittent claudication (10.9% [44 patients] and 9.4% [38 patients], respectively). CONCLUSIONS: In this randomized trial in which patients with peripheral artery disease received treatment with paclitaxel-coated or uncoated endovascular devices, the results of an unplanned interim analysis of all-cause mortality did not show a difference between the groups in the incidence of death during 1 to 4 years of follow-up. (Funded by the Swedish Research Council and others; ClinicalTrials.gov number, NCT02051088.).

A significant correlation between body surface area and infrarenal aortic diameter is detected in a large screening population with possibly clinical implications.

BACKGROUND: Screening for abdominal aortic aneurysm (AAA) in elderly men reduces aneurysm related mortality. AAA is commonly defined as an infrarenal aortic diameter (IAD) of ≥30 mm, which is based on the definition of an arterial aneurysm as a focal dilation of 150% or more compared to the expected diameter of about 20 mm. The IAD has been shown to correlate to body surface area (BSA). The aim of this study was to investigate the possibility to use an individualized AAA-criteria by using a BSA-based model to refine the screening for AAA. METHODS: We conducted an observational single center cohort study of 25 236 65-year old men invited to AAA screening in Malmö, Sweden 2010-2015. Out of the 19 738 (78.5%) attendees, 14 846 (58.8%) completed a health questionnaire including height, weight and smoking habits. Linear regression analysis was performed between BSA and IAD, taking smoking habits into account. This regression was used to calculate the predicted IAD for each individual according to their BSA. RESULTS: There was a significant correlation between BSA and aortic diameter, rho =0.26 (95% CI: 0.25, 0.28). AAA defined as an IAD≥30 mm was found in 226 men (1.5%) whereas AAA defined as ≥150% larger IAD than predicted according to the individual BSA was found in 299 men (1.9%), a relative difference in AAA detection rate of more than 30% (P<0.001). CONCLUSIONS: We have found a statistically significant correlation between BSA and IAD in a homogenous screening population that could have clinical implications. In men with low BSA, IAD <30 mm might still be ≥150% larger than predicted according to BSA, whereas in men with high BSA, IAD≥30 mm might not be ≥150% larger than predicted. Further follow-up of these subjects is planned to investigate if the first group have an "aneurysm-in-formation," challenging the diagnostic criteria for AAA.